Journal
CANCER RESEARCH
Volume 74, Issue 1, Pages 201-211Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-13-1175
Keywords
-
Categories
Funding
- University of Cincinnati College of Medicine
- Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program
- Canadian Cancer Society Research Institute
- Cancer Research Society
- Canadian Institutes for Health Research
Ask authors/readers for more resources
Deregulation of translation initiation factors contributes to many pathogenic conditions, including cancer. Here, we report the definition of a novel regulatory pathway for translational initiation with possible therapeutic import in cancer. Specifically, we found that casein kinase 1 epsilon (CK1 epsilon) is highly expressed in breast tumors and plays a critical role in cancer cell proliferation by controlling mRNA translation. Eukaryotic translation initiation factor eIF4E, an essential component of the translation initiation complex eIF4F, is downregulated by binding the negative-acting factor 4E-BP1. We found that genetic or pharmacologic inhibition of CK1e attenuated 4E-BP1 phosphorylation, thereby increasing 4E-BP1 binding to eIF4E and inhibiting mRNA translation. Mechanistic investigations showed that CK1 epsilon interacted with and phosphorylated 4E-BP1 at two novel sites T41 and T50, which were essential for 4E-BP1 inactivation along with increased mRNA translation and cell proliferation. In summary, our work identified CK1 epsilon as a pivotal regulator of mRNA translation and cell proliferation that acts by inhibiting 4E-BP1 function. As CK1 epsilon is highly expressed in breast tumors, these findings offer an initial rationale to explore CK1 epsilon blockade as a therapeutic strategy to treat cancers driven by deregulated mRNA translation. (C)2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available